Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Sonpavde on Fixed-Dose Durvalumab and Tremelimumab Study in Urothelial Carcinoma

February 10th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a phase IIIb safety study of fixed-dose durvalumab (Imfinzi) and tremelimumab in patients with advanced urothelial carcinoma.

Olaparib/Durvalumab Combo Shows Promise in mCRPC

February 9th 2018

The PARP inhibitor olaparib appeared to complement the antitumor activity of the PD-L1 inhibitor durvalumab in unselected men with metastatic castrate-resistant prostate cancer, according to findings from a phase II study presented at the 2018 Genitourinary Cancers Symposium.

Dr. Joshi Discusses Durvalumab and Radiation Therapy in Bladder Cancer

February 9th 2018

Monika Joshi, MD, assistant professor, Penn State Hershey Medical Center, discusses a phase Ib study of durvalumab (Imfinzi) and radiation therapy (DUART) followed by adjuvant durvalumab in patients with urothelial carcinoma.

Robotic Approaches Advancing Surgical Scope in Muscle-Invasive Bladder Cancer

February 7th 2018

William C. Huang, MD, discusses the transition from open cystectomy to minimally invasive robotic-assisted surgery in the management of muscle-invasive bladder cancer.

Dr. Hammers on the Future of Immunotherapy in RCC

February 7th 2018

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of immunotherapy for patients with renal cell carcinoma (RCC).

Organ Preservation Approaches in Muscle-Invasive Bladder Cancer

February 7th 2018

Selective bladder preservation has been suggested as a potential alternative to cystectomy in patients with bladder cancer who have a transitional cell carcinoma pathology.

Dr. Voss on the Case for Neoadjuvant Treatment in Kidney Cancer

February 6th 2018

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the case for neoadjuvant therapy in the treatment of kidney cancer.

New Model Predicts Survival Following Treatment With Atezolizumab for Bladder Cancer

February 6th 2018

A new model based on 6 clinical factors may be able to predict overall survival for patients with advanced urothelial cancers being treated with the PD-L1 inhibitor atezolizumab.

Atezolizumab Combo Improves PFS by 3.5 Months in mRCC

February 6th 2018

The combination of atezolizumab and bevacizumab reduced the risk of progression or death by 26% compared with sunitinib for patients with untreated PD-L1–positive metastatic renal cell carcinoma.

Balar Addresses Advances in Bladder and Kidney Cancer

February 5th 2018

Arjun V. Balar, MD, discusses the landscape of current and future standards of care for immunotherapy in bladder and kidney cancer.

Can Immunotherapy Bypass Sequential Care in RCC?

February 2nd 2018

Despite positive clinical trial results, the role of immunotherapy in renal cell carcinoma remains unclear.

Cabozantinib QoL Similar to Everolimus in RCC Patients

February 2nd 2018

Patients with advanced renal cell carcinoma treated with cabozantinib had similar quality of life outcomes as those treated with everolimus.

Dr. Balar on Current and Future Standards of Care in Kidney Cancer Treatment

January 30th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the potential of existing targeted therapy coupled with immunotherapy to improve overall survival (OS) in patients with kidney cancer.

Dr. Huang Discusses Robotic Surgery for Bladder Cancer

January 27th 2018

William C. Huang, MD, associate professor, department of Urology, co-director, Robotics Program, Chief Urology Service, Tisch Hospital, NYU Langone Health, discusses robotic surgery in the treatment of bladder cancer.

Dr. Zhang Discusses Neoadjuvant Therapy in Kidney Cancer

January 25th 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses neoadjuvant therapy in kidney cancer.

Dr. McKay Discusses Combinations in Renal Cell Carcinoma

January 24th 2018

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses combinations in renal cell carcinoma.

Cabozantinib Improves Survival in RCC Patients With Bone Metastases

January 23rd 2018

Cabozantinib (Cabometyx) was associated with an improvement in overall survival and progression-free survival compared with everolimus (Afinitor) in pretreated patients with advanced RCC with bone metastases at baseline.

Dr. McDermott on Novel Immunotherapy Combinations in RCC

January 20th 2018

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses novel immunotherapy combinations for patients with metastatic renal cell carcinoma (RCC).

Dr. Apolo on Managing Toxicities of Checkpoint Inhibitors in Bladder Cancer

January 19th 2018

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing immune-related toxicities from checkpoint inhibitors in patients with bladder cancer.

Published Data Demonstrate Avelumab Activity in Platinum-Refractory Bladder Cancer

January 18th 2018

The PD-L1 inhibitor avelumab induced an overall response rate of 17% in patients with platinum-refractory metastatic urothelial carcinoma.